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Abstract. Aim: To report on clinical outcomes of a
consecutive series of locally advanced (T3-T4N0-N3) anal
cancer patients treated with intensity-modulated
radiotherapy (IMRT) and a simultaneous integrated boost
(SIB) approach similarly to the RTOG 05-29 trial. Patients
and Methods: A cohort of 45 patients underwent SIB-IMRT
employing a schedule consisting of 54 Gy/30 fractions to the
macroscopic anal planning target volume (PTV), while
clinical nodes were prescribed 50.4 Gy/30 fractions if sized
≤3 cm or 54 Gy/30 fractions if >3 cm. Elective nodal PTV
was prescribed 45 Gy/30 fractions. Chemotherapy was
administered concurrently following the Nigro regimen.
Primary end-point was colostomy-free survival (CFS).
Secondary end-points were locoregional control (LRC),
disease-free survival (DFS), cancer-specific survival (CSS)
and overall survival (OS). Results: Median follow-up was
39.7 months. The actuarial 3-year CFS was 63.4 % (95%
confidence interval (CI=44.8-77.1%). Actuarial 3-year OS
and CSS were 67.7% (95%CI=48.7-80.9%) and 72.9%
(95%CI=53.8-85.1%), while DFS was 55.8%
(95%CI=37.5.4-70.7%). Actuarial 3-year LRC was 74.1%
(95%CI=56.7-85.4%). On multivariate analysis, male sex
(hazard ratio (HR)=10.9; p=0.004; 95%CI=2.2-55.5%) had
a significant impact on CFS, while higher clinical stage
(Stage IIIB vs. others) had borderline significance (HR=2.7;
p=0.062; 95%CI=1.8-5.9%). A shorter package time
(HR=0.94; p=0.007; 95%CI=0.91-0.98%) predicted for
higher CFS. Maximum detected events included: skin (G3):
13%; gastrointestinal (GI) (G3): 13%; genitourinary (GU)
(G2): 38%; genitalia (G2): 45%; anemia (G2): 4%;
leukopenia (G3): 24%, (G4):7%; neutropenia (G3): 16%;
(G4): 11%; thrombocytopenia (G3): 9%, (G4): 2%.
Conclusion: Our clinical results support the use of SIB-IMRT
in the combined modality treatment of locally advanced anal
cancer patients.
Tumors arising in the anal cancer are thought to be a rare
clinicopathological entity, since they account for 6% of all
cancers within the anorectal region and for the same
percentage of all malignancies of the gastrointestinal tract (1).
Concurrent chemoradiation (CT-RT) is considered a standard-
of-care in this context as it provides consistent rates of
locoregional control (LRC) and colostomy-free survival (CFS)
(2, 3). While in early-stage disease, combination therapy is
still an option under debate, in locally advanced disease with
either T3-T4 tumors or nodal involvement, CT-RT is a well-
established solution (2-7). Intensity-modulated radiotherapy
(IMRT) is a treatment strategy, that can deliver radiation with
robust conformality and modulation, abrupt dose fall-off and
reliable consistency and, hence, is a suitable tool in several
oncological scenarios (8, 9). IMRT can be performed using a
simultaneous integrated boost (SIB) approach, which allows
dispensing different daily doses to different target volumes
during the same treatment fraction (10). SIB has been
demonstrated to consistently spare normal tissues and has been
investigated also in anal cancer patients (11, 12). The RTOG
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05-29 phase II study investigated the potential of dose-painted
IMRT in reducing by at least 15% the ≥G2 gastrointestinal
(GI) and genitourinary (GU) acute toxicity rates, compared to
the 5-fluorouracil (5FU)-mytomicin C (MMC) arm of the
RTOG 98-11 trial where radiotherapy was mainly delivered
with non-conformal techniques (13, 14). Having as primary
end-point acute toxicity profile, RTOG 05-29 has not yet
provided data on LRC and overall survival (OS). Hence, we
decided to retrospectively analyze outcomes of a consecutive
series of locally advanced anal cancer patients, treated at our
Institution with IMRT and SIB according to RTOG 05-29
protocol.
Materials and Methods
Eligibility criteria and baseline evaluation. All patients included in
the present analysis presented with squamous cell anal cancer and
were submitted to definitive radiotherapy (RT) at the Department of
Radiation Oncology of the University of Turin, Italy. Staging was
made according to the 2002 American Joint Committee on Cancer
classification. Enrolled patients had locally advanced disease (cT3-
T4N0M0 or node positive disease). Written informed consent was
obtained for all patients. Patients underwent clinical evaluation by
the gastrointestinal tumor board of our Institution, including past
clinical history, digital rectal examination and anoscopy, complete
blood count, thoracic and abdominal computed tomography (CT),
pelvic magnetic resonance (MR) and 18FDG-PET and/or inguinal
sentinel lymphnode biopsy.
Radiotherapy. Patients underwent a 3-mm slice thickness planning
CT scan in supine position with both an indexed shaped knee rest and
ankle support (CIVCO Medical Solutions, Kalona, IA, USA). The
gross tumor volume (GTV) included all primary and nodal
macroscopic disease and was expanded with 2 and 1 cm margin,
respectively, to obtain subsequent clinical target volumes (CTVs) and
then modified to spare bones and soft tissues. The prophylactic CTV
included the mesorectal region and regional groin areas. Nodal
regions were outlined with a 1 cm isotropic margin around regional
vessels and then corrected to exclude bones and muscles. A 10-mm
isotropic margin was added for the corresponding planning target
volume (PTV). Dose prescription for target volumes was taken from
Kachnic et al. and was based on a SIB approach (13). Patients staged
as cT3-T4/N0-N3 were given 54 Gy/30 fractions to the macroscopic
anal PTV, while clinical nodes were prescribed 50.4 Gy/30 fr if sized
≤3 cm or 54 Gy/30 fr if >3 cm. Elective nodal PTV was prescribed 45
Gy/30 fractions (13). Objectives for target volumes were set so that,
for PTV, V95 should be at least 95%, V110 ≤10% and ≤2% should
receive <95% of prescribed dose. Dose constraints for organs at risk
(OARs) were inspired by Kachnic et al. (15). To compute volumetric
modulated arc therapy (VMAT), Elekta Monaco was used as
treatment planning system (version 3.2) employing a 360˚ single-arc
or the dual-arc approach after system upgrade. For step and shoot
IMRT, plans were generated with up to 7 modulated fields, employing
6 MV photons, according to patients’ anatomy. RT was performed
under daily cone beam CT (CBCT) image guidance.
Chemotherapy. All patients received concurrent chemotherapy (CT),
consisting of 5- fluorouracil (1,000 mg/m2/day) given as continuous
infusion along 96 hours (days 1-5 and 29-33) associated with
mitomycin C (10 mg/m2) given as bolus (days 1 and 29). A total of
2 concurrent cycles were planned at baseline for each patient. 
Clinical assessment. Acute toxicity was scored according to the
Common Toxicity Criteria for Adverse Events scale v3.0, evaluating
GU, GI, hematologic, dermatologic, genital and osseous events. The
worst toxicity for each category was considered. Follow-up included
digital rectal examination and anoscopy at 4, 8, 12 and 26 weeks.
MRI was performed at 12 weeks and an anal canal bioptic sampling
was done at 26. If no residual disease was found at pathology,
patients were classified as complete responders. Salvage abdomino-
perineal resection was offered for persistent disease (at pathology)
or for locally progressive or recurrent disease (at imaging and
pathology). Conservative salvage treatment strategies were also
considered if appropriate.
Statistical analysis. Disease recurrence was defined as local when
detected in the anal canal and/or anal margin and/or mesorectum.
Regional relapse included evidence of disease at draining nodes,
while systemic recurrence comprised distant metastasis. For LRC,
we took into account local and regional failures. Metastasis-free
survival (MFS) included failures other than those occurring in the
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Table I. Patients’ and tumor characteristics.
Variable N (%)
Age
Mean 62
Range 34-79
Gender
Female 35 (78)
Male 10 (22)
HIV status
Positive 3 (7)
Negative 42 (93)
Primary tumor site
Anal canal 38 (84)
Anal margin 7 (16)
T stage
T2 17 (38)
T3 24 (53)
T4 4 (9)
N stage
N0 15 (33)
N1 5 (11)
N2 21 (47)
N3 4 (9)
Global stage
II 13 (29)
IIIA 8 (18)
IIIB 24 (53)
Grading
G1 3 (7)
G2 29 (64)
G3 13 (29)
Prophylactic colostomy
Yes 0 (0)
No 45 (100)
anal region and regional nodes. For cancer-specific survival (CSS),
we took into account death due to disease. OS considered death
of any cause. Disease-free survival (DFS) included all failures and
cancer-related deaths. CFS accounted for death of any cause or
definitive colostomy. Kaplan-Meier method was used to calculate
survival curves and actuarial rates of relapse. Wilcoxon signed-
rank test was used to perform univariate analysis. Multivariate
analysis was performed using stepwise Cox proportional hazard
regression models and related. Eventual correlation between
clinical prognostic factors and CFS was tested. Covariates
included in the analysis were sex, age, stage, grading overall
treatment time (OTT) (days), time between biopsy and
radiotherapy start (days) and between biopsy and radiotherapy end
(days), called ‘package time’. Stata Statistical Software, version
13.1 (Stata Corporation, College Station, TX, USA) was employed
for analysis.
Results
A total of 45 patients were treated between June 2007 and June
2015. Details of patients’ characteristics can be found in Table
I. Mean age was 62 (range=34-79). They were mainly female
(78%), HIV-negative (93%), with an anal canal primary (84%),
T2-T3 (91%) and N1-N2 (58%) stage and G2 (64%) grading.
Patients were mainly treated with VMAT technique (58%).
Most of the patients received 54 Gy/30 fractions on the primary
tumor-PTV (84%), 50.4 Gy/30 fractions on the macroscopic
nodes (42%) and 45 Gy/30 fractions on the prophylactic nodal
PTV (91%). Most patients received 5-FU/MMC- based CT
(91%) for a total of 2 cycles (95%). The mean time from
biopsy to start of IMRT was 68 days. Mean OTT was 44 days.
Mean package time was 112 days. Patients with breaks ≥3 days
were 5%. Details are given in Table II.
Toxicity profile. Acute toxicity profile is shown in Table III.
Maximum detected events included: skin (G3): 13%; GI
(G3): 13%; GU (G2): 38%; genitalia (G2): 45%; anemia
(G2): 4%; leukopenia (G3): 24%, (G4):7%; neutropenia
(G3): 16%; (G4): 11%; thrombocytopenia (G3): 9%; (G4):
2%. Moist desquamation (skin), diarrhea with more than 7
stools per day (GI) and cystitis interfering with activities of
daily living (GU) were considered as G3 events. 
Clinical outcomes. Median follow-up time was 36 months
(range=6-105). Globally, 15 treatment failures were
observed. A total of 4 patients experienced locoregional
relapse only after combined CT-RT, while 5 had distant
spread as an exclusive pattern of failure (liver and lung). Up
to 6 patients had both locoregional and metastatic failure. A
total of 6 patients were salvaged with abdomino-perineal
resection and definitive colostomy. One patient relapsing
within the anal margin underwent local excision and
subsequent adjuvant interstitial brachytherapy. All metastatic
patients received chemotherapy as part of their salvage
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Table II. Treatment characteristics. 
Variable N (%)
IMRT approach
Step and shoot 19 (42)
VMAT 26 (58)
PTV dose-tumor (Gy)
54 Gy/30 fractions 38 (84)
50.4 Gy/28 fractions 7 (16)
PTV dose-positive nodes (Gy)
54 Gy/30 fractions 2 (5)
50.4 Gy/30 fractions 19 (42)
PTV dose-negative nodes (Gy)
45 Gy/30 fractions 41 (91)
42 Gy/28 fractions 4 (9)
Chemotherapy
5-FU + MMC 41 (91)
5-FU 1 (2)
MMC 1 (2)
None 2 (5)
Cycles
1 2 (5)
2 41 (95)
Chemotherapy dose reduction
Yes 4 (9)
No 39 (91)
Biopsy-RT interval (days)
Mean 68
Range 25-159
RT duration (days)
Mean 44
Range 37-59
Package time
Mean 112
Range 68-211
RT breaks ≥3 days
Yes 2 (5)
No 43 (95)
IMRT: Intensity-modulated radiotherapy; PTV: planning target volume;
RT: radiotherapy; 5-FU: 5-fluorouracil; MMC: mytomicin C. 
Table III. Acute toxicity profile.
N(%)
Acute toxicity G0 G1 G2 G3 G4
Skin 1 (2) 4 (9) 34 (76) 6 (13) 0
Gastrointestinal 0 11 (25) 28 (62) 6 (13) 0
Genitourinary 6 (13) 22 (49) 17 (38) 0 0
Genitalia 2 (4) 23 (51) 20 (45) 0 0
Anemia 23 (51) 20 (45) 2 (4) 0 0
Leukopenia 7 (16) 11 (24) 13 (29) 11 (24) 3 (7)
Neutropenia 14 (31) 10 (22) 9 (20) 7 (16) 5 (11)
Thrombocytopenia 25 (56) 10 (22) 5 (11) 4 (9) 1 (2)
treatment. Overall, 16 patients died. Twelve events were
cancer-related, while other 4 were due to other causes.
Actuarial 3-year OS and CSS were 67.7% (95% confidence
interval (CI)=48.7-80.9%) and 72.9% (95%CI=53.8-85.1%)
(Figure 1a and 1b). Actuarial 3-year LRC was 74.1%
(95%CI=56.7-85.4%) (Figure 1c). Actuarial 3-year DFS was
55.8% (95%CI=37.5.4-70.7%) (Figure 1d). Three-year MFS
was 76.2% (95%CI=56.1-87.9%) (Figure 2). The actuarial
probability of being alive at 3 years without a colostomy
(CFS) was 63.4 % (95%CI=44.8-77.1%) (Figure 3). On
multivariate analysis, male sex (hazard ratio (HR)=10.9;
p=0.004; 95%CI=2.2-55.5%) had a significant impact on
CFS, while higher clinical stage (Stage IIIB vs. others) had
borderline significance (HR=2.7; p=0.062; 95%CI=1.8-
5.9%). A shorter package time (HR=0.94; p=0.007;
95%CI=0.91-0.98%) has been shown to be a protective
factor towards the occurrence of death and definitive
colostomy.
Discussion
Concomitant RT-CT is presently pointed out as a standard
therapeutic option in patients affected with anal cancer (2).
Recent multidisciplinary guidelines indicate this treatment
option as appropriate in all clinical stages, excluding T1-
tumors arising from the anal margin (16). For instance, most
of the data coming from prospective randomized phase III
trial can be extrapolated from the context of locally advanced
disease (T3-T4, N+), where combination therapy is widely
established, while CT addition still remains under debate in
early-stage disease (T1-T2) (6). For example, the European
Organization for Research and Treatment of Cancer
(EORTC) trial included only locally advanced disease,
excluding from accrual T1-T2 node negative patients (3).
More than a half of patients enrolled in the ACT I study were
staged as T3-T4 and up to 20% of them had palpable nodal
disease, while cases staged as T1N0 were excluded (2). In
the ACT II trial, 46% of patients had T3-T4 tumors and 32%
had positive regional lymphnodes (15). In the RTOG 98-11
study, 35% of patients had T3-T4 disease and 26% presented
with clinically positive lymphnodes (14). The EORTC is the
most comparable study to our consecutive case series. It
compared exclusive radiotherapy to combination therapy
(with 5-FU and MMC) in locally advanced disease on 110
patients affected with cT3-T4/N0-N3 or cT1-T2/N1-N3 anal
cancer (3). Radiotherapy was given up to a total dose of 45
Gy over 5 weeks using conventional fractionation to the
whole pelvis followed, after a 6-week interval, by a boost
dose modulated according to treatment response (20 Gy to
partial and 15 Gy to complete responders). Salvage surgery
was reserved to non-responders 6 weeks after the first 45 Gy
delivered or to patients with residual palpable disease after
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Figure 1. Overall survival (a), cancer-specific survival (b), local control (c), disease-free survival (d).
the whole treatment course. In the CT-RT arm of the study,
progression-free survival (PFS) was around 48% at 3 years.
Actuarial 3-year OS was around 68%, while 3-year CFS was
around 73%. Among treatment outcomes, authors reported
also on event-free survival (EFS) defined as being free from
local progression, colostomy, death and severe late
complications (stenosis, severe rectal bleeding, skin or anal
canal ulceration, fistula, perforation and severe fibrosis),
which in the combined modality treatment arm was around
30% (3). In our series, actuarial rates of OS, DFS and CFS
were 67.7%, 55.8% and 63.4%, respectively. Those results
compare similarly to EORTC data, except for CFS, which
was found to be lower in our series whose case mix was
rather unfavorable with more than half of the patients staged
as IIIB. The end-point described by the EORTC trial, namely
EFS, takes into account both tumor control at any site and
long-term toxicity profile. Reported rates in that study were
extremely poor, in particular around 30% at 3 years. That
means, in practice, that patients either developed treatment
failure, eventually dying of that, or experienced RT-CT
induced long-term sequelae. This consideration points out
the importance of both OTT contraction and optimal
radiation delivery in order to decrease acute and chronic
toxicity profile. The EORTC trial delivered radiation with a
6-week interval between the whole-pelvis and the boost
phase, leading to a consistent OTT with a potential
detrimental effect on treatment outcomes. In fact, PFS was
as low as 48% in this study. For a rapidly repopulating
tumor, such as squamous cell anal cancer, the reduction of
treatment delivery time is crucial. The 5FU/MMC arm of
the RTOG 98-11 trial had a mean OTT of 49 days (14). In
the RTOG 05-29, mean OTT was 43 days, comparably to
our series (44 days) (13). This contraction in OTT is made
possible by the use of SIB-based IMRT, which is able to
deliver different daily doses to different treatment volumes
within the same fraction (12). The effective time of
radiation delivery is important, but also the global duration
of diagnostic procedures and staging work-up is focal. In
our series, a shorter package time was found to be
predictive of a lower likelihood to experience death or
definitive colostomy (HR=0.94; p=0.007; 95%CI=0.91-
0.98%). The other key point is toxicity profile as it affects
both patient’s quality of life and treatment global intensity.
Our patient cohort underwent a treatment strategy similar
to the RTOG 05-29 trial using IMRT and SIB (13). The
RTOG 05-29 phase II study was designed to assess whether
dose-painted IMRT could reduce by at least 15% the ≥G2
GI and GU toxicity rates, compared to conventional
radiation and concurrent 5-FU/MMC as delivered in the
standard arm of RTOG 98-11 trial, which employed non-
conformal techniques, namely anterior-posterior parallel-
opposed fields or 4-field conformal beam arrangements (13,
14). In the aforementioned trial, the primary end-point was
not reached, but the study demonstrated a significant
decrease in acute G2 hematologic (73% vs. 85 % for RTOG
98-11), G3 GI (21% vs. 36% for RTOG 98-11) and G3
dermatologic acute adverse events (23% vs. 49% for RTOG
98-11) compared to standard radiation (13, 14). Similarly,
our results showed a reasonable toxicity profile with a mild
rate of major events. Our data support the use of SIB-IMRT
delivered with concurrent 5FU/MMC-based CT similarly to
the RTOG 05-29 protocol with consistent clinical outcomes
and acceptable side effects in locally advanced anal cancer
patients. Treatment intensification either with dose-
escalation or with other adjunctive drugs, such as targeted
therapies, may be suggested for patients having high-risk
features, such as male sex and advanced nodal stage.
However, a focused attention should be paid to avoid
treatment breaks and unintended delays in the diagnostic
and therapeutic process (18). 
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Figure 3. Colostomy-free survival. Figure 2. Metastasis-free survival. 
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